Title: Quantification of serum p53 antibodies:An independent prognostic factor in advanced non-small cell lung cancer
Abstract: Objective To explore the prognostic value of quantification of serum p53 antibody(p53-Ab) level in patients with advanced non-small cell lung cancer(NSCLC).Methods Serum samples were obtained from 60 patients with histologically confirmed advanced NSCLC and 30 healthy volunteers.The serum p53-Abs was quantitatively assessed by enzyme-linked immunosorbent assay.The patients with NSCLC were followed up intensively.Results The median p53-Abs level was 0.77 IU/mL(0.60~1.07 IU/mL) in the health volunteers and 1.75 IU/mL(0.61~12.00 IU/mL) in the patients with NSCLC.The difference was statistically significant.In patients with NSCLC,the p53-Abs level was positively correlated to the serum level of CEA and CA125(P0.05),had no correlation with CA242 and CA153(P0.05),was higher in non-squamous carcinoma than in others(P0.05),and marginally correlated to chemoresistance(P=0.06).When p53-Ab level of 3.65 IU/mL was used as a cutoff point,the patients with elevated p53-Abs had significantly shortened overall survival(median OS: 8.5 months vs 18.9 months,P=0.047).Cox model showed that p53 level and chemo-ineffective were independent prognostic factors.Conclusions The serum p53-Ab level is related to NSCLC chemoresistance and an independent prognostic factor.Quantification of serum p53 Abs may help to tailor the treatment for advanced NSCLC.
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot